EA5182 Randomized phase 3 study of combination azd9291 (osimertinib) and bevacizumab versus azd9291 (osimertinib) alone as first-line treatment for patients with metastatic egfr-mutant non-small cell lung cancer

  • Phase III
  • Trial Category: Lung

Contact(s)

Mary Beth Wilwerding, RN   Admin@NEcancertrials.com

Location(s)

Available at Cancer Partners of Nebraska, Lincoln and Kearney, NE locations

Interested in More Information?

Please fill out the form below. Someone will get back to you as soon as possible.

"*" indicates required fields

Name*